C4orf3

Across TCGA pan-cancer cohorts, C4orf3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of C4orf3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where C4orf3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types C4orf3 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where C4orf3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C4orf3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	+1.448	<.001	12	view →
HNSC	Male	III,IV	+0.430	<.001	8	view →
COAD	All	II,III,IV	+0.290	.001	7	view →
LSCC	Male	II,III,IV	+0.388	<.001	6	view →
LUAD	Male	All	+0.187	.014	3	view →
PDAC	Male	All	−0.556	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

C4orf3–CCRCC

Open the CCRCC breakdown →